Analyst Price Targets — BNTC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 24, 2025 11:16 am | Raghuram Selvaraju | H.C. Wainwright | $32.00 | $13.26 | TheFly | Benitec Biopharma price target lowered to $32 from $35 at H.C. Wainwright |
| November 4, 2025 5:30 pm | — | H.C. Wainwright | $35.00 | $15.69 | TheFly | Benitec Biopharma price target raised to $35 from $28 at H.C. Wainwright |
| November 4, 2025 10:42 am | — | JMP Securities | $22.00 | $15.86 | TheFly | Benitec Biopharma price target raised to $22 from $20 at Citizens JMP |
| September 16, 2025 12:08 pm | Andreas Argyrides | Oppenheimer | $29.00 | $13.66 | TheFly | Benitec Biopharma price target lowered to $29 from $35 at Oppenheimer |
| October 14, 2024 8:24 am | Silvan Tuerkcan | JMP Securities | $18.00 | $10.86 | TheFly | Benitec Biopharma price target raised to $18 from $16 at JMP Securities |
| October 14, 2024 6:36 am | Silvan Tuerkcan | JMP Securities | $16.00 | $10.86 | TheFly | Benitec Biopharma price target lowered to $16 from $18 at JMP Securities |
| October 14, 2024 6:05 am | Mani Foroohar | Leerink Partners | $13.00 | $10.86 | StreetInsider | Leerink Partners Reiterates Outperform Rating on Benitec BioPharma (BNTC) |
| September 24, 2024 7:53 am | Yasmeen Rahimi | Piper Sandler | $30.00 | $8.88 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Benitec BioPharma (BNTC) |
Latest News for BNTC
-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first Cohort 1 Patient, and interim clinical study results for the first Cohort 2 Patient will be reported in a late-breaking poster presentation at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on…
Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint
Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report) Director Suvretta Capital Management, L purchased 50,000 shares of Benitec Biopharma stock in a transaction that occurred on Tuesday, December 23rd. The shares were purchased at an average cost of $12.85 per share, with a total value of $642,500.00. Following the transaction, the director directly owned 9,620,075
Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report) Director Suvretta Capital Management, L bought 16,836 shares of the firm's stock in a transaction that occurred on Friday, December 26th. The stock was purchased at an average cost of $13.10 per share, with a total value of $220,551.60. Following the completion of the purchase, the director
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BNTC.
U.S. House Trading
No House trades found for BNTC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.